Q-omics provides the consensus-scored RPL12P30 profile across patient tissues and cancer cell-line models. RPL12P30 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL12P30 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, RPL12P30 RNA expression shows 15,495 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where RPL12P30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL12P30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL12P30 survival associations across molecular data types. RPL12P30 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL12P30 RNA expression–survival associations across cancer types. High RPL12P30 expression shows unfavorable associations in DLBC and LUAD, but favorable associations in KIRC, BLCA, ACC and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL12P30 RNA expression.
This table summarizes RPL12P30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL12P30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL12P30 shows lower tumor expression in KIRC, THCA, KIRP, BRCA and PRAD and higher tumor expression in LIHC. The KIRC box plot shows higher RPL12P30 RNA expression in normal versus tumor tissue (log2 FC = −1.062, t-test p < 0.001).
This table shows molecular features associated with RPL12P30 in patient tissues and cancer cell lines. In patient samples, RPL12P30 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
